Navigation Links
Ambit Biosciences to Present at Two Upcoming Investor Conferences
Date:2/9/2012

SAN DIEGO, Feb. 9, 2012 /PRNewswire/ -- Ambit Biosciences today announced that Michael A. Martino, Ambit's president and chief executive officer, will provide an overview of the company and an update about its clinical development programs, including quizartinib, at two upcoming investor conferences at the Waldorf Astoria in New York City.

  • 14th Annual BIO CEO & Investor Conference
    • Presentation: 1:30 p.m. EST on Monday, February 13, 2012
  • Leerink Swann 2012 Global Healthcare Conference
    • Presentation: 8 a.m. EST on Thursday, February 16, 2012

About Quizartinib
Quizartinib, formerly known as AC220, is being developed in collaboration between Ambit Biosciences and Astellas Pharma Inc. and is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor.  Quizartinib is currently under evaluation in a Phase 2 clinical trial as monotherapy treatment for adult and elderly patients with relapsed/refractory AML that have an internal tandem duplication (ITD) mutation in the FLT3 gene.

About Ambit Biosciences
Ambit Biosciences is a privately held biopharmaceutical company engaged in the development of a robust pipeline of small molecule kinase inhibitors for the treatment of cancer, inflammatory disease and other indications. Ambit's lead compound, quizartinib (AC220), is a novel, potent, highly selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor, and is currently under clinical investigation in patients with relapsed or refractory AML. Ambit is developing quizartinib in collaboration with Astellas Pharma Inc. as part of a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications. In addition to quizartinib, Ambit's clinical pipe
'/>"/>

SOURCE Ambit Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
2. Ambit Biosciences Announces Transition in Company Leadership
3. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
4. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
5. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
6. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
7. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
8. Milestone Biosciences, LLC Further Strengthens Executive Management Team
9. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
10. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
11. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015  Juniper Pharmaceuticals, ... focused on developing therapeutics that address unmet medical ... George Elston will present at the ... Wednesday, July 8, 2015Time: , 4:45 PM EDTLocation: ... (live & archive): , www.juniperpharma.com, under  ,Investor, ...
(Date:6/30/2015)... ... June 30, 2015 , ... Noblis, Inc., a leading provider ... paper published this week in the scientific journal Viruses ( http://www.mdpi.com/1999-4915/7/6/2763 ), that ... used to detect the Ebola virus. Noblis worked with the Department of Defense’s ...
(Date:6/30/2015)... HAUPPAUGE, N.Y. , June 30, 2015  Custom ... provider, announced today that they are silver sponsors of ... an official PCDC sponsor, Custom is lending their support ... in low-income communities. Since its founding in ... for the primary care area.  PCDC has financed over ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... SmartArch — a revolutionary new archwire that allows orthodontists to simultaneously apply different ... of the efficacy of SmartArch. “We’re thrilled about taking SmartArch one step closer ...
Breaking Biology Technology:Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 4Custom Computer Specialists Announces Sponsorship Of The Primary Care Development Corporation's Corporate Circle 2New case studies for SmartArch orthodontic archwire paves way to product launch later this year 2
... Trusted LASIK Surgeons directory service and website at ... consumers seeking to improve their vision and find a ... of attaining 20-20 vision. What sets the Trusted ... ensuring that only those who are among the best ...
... to Leverage Bio-Tech Medical Software, Inc. with the University ... UCF,s biometrics, elite technology and other programming techniques in ... Fla., March 11 Bio-Tech Medical Software, Inc. a ... by the University of Central Florida , UCF ...
... SOUTH SAN FRANCISCO, Calif., March 10 Poniard Pharmaceuticals, ... focused on innovative oncology therapies, today announced that it ... and year-end 2008 financial results, which was previously scheduled ... 8:30 a.m. Eastern Time, in order to complete its ...
Cached Biology Technology:Trusted LASIK Surgeons Welcomes Leading Laser Expert and Inventor Jon Dishler, M.D., to Its Unique LASIK Eye Surgeon Directory for Consumers 2Trusted LASIK Surgeons Welcomes Leading Laser Expert and Inventor Jon Dishler, M.D., to Its Unique LASIK Eye Surgeon Directory for Consumers 3Trusted LASIK Surgeons Welcomes Leading Laser Expert and Inventor Jon Dishler, M.D., to Its Unique LASIK Eye Surgeon Directory for Consumers 4Trusted LASIK Surgeons Welcomes Leading Laser Expert and Inventor Jon Dishler, M.D., to Its Unique LASIK Eye Surgeon Directory for Consumers 5Trusted LASIK Surgeons Welcomes Leading Laser Expert and Inventor Jon Dishler, M.D., to Its Unique LASIK Eye Surgeon Directory for Consumers 6Trusted LASIK Surgeons Welcomes Leading Laser Expert and Inventor Jon Dishler, M.D., to Its Unique LASIK Eye Surgeon Directory for Consumers 7Trusted LASIK Surgeons Welcomes Leading Laser Expert and Inventor Jon Dishler, M.D., to Its Unique LASIK Eye Surgeon Directory for Consumers 8Bio-Tech Medical Software, Inc. Biometrics Joins Forces with the University of Central Florida to Fight Diversion and Help Combat Prescription Narcotic Drug Abuse 2Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16 2
(Date:6/23/2015)... 2015   MedNet Solutions , an innovative ... spectrum of clinical research, is pleased to announce ... the company,s intuitive, flexible and affordable cloud-based eClinical ... Stevie® Award by the American Business Awards ... category.  The American Business Awards are considered the ...
(Date:6/18/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market announces that its Wocket® smart wallet ... on the Mark", scheduled to air on WABC Radio (am770) ... th . The broadcast air- time for ... 8:00pm EST. NXT-ID, Inc.,s CEO Gino Pereira will ...
(Date:6/16/2015)... 16, 2015 /CNW Telbec/ - handyem Inc. and ... the incorporation of handyem,s HPC-150 portable flow cytometer ... Mo-POD™. This unprecedented model of mobile laboratory platform ... the Pennsylvania Convention Center, ... th to 18 th 2015.  By ...
Breaking Biology News(10 mins):MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3
... research shows an increased risk of ischemic stroke in postmenopausal ... found in baked goods, fried foods, and packaged products. Study ... journal published by Wiley-Blackwell on behalf of the American Neurological ... the stroke risk caused by a diet high in trans ...
... NY, February 29, 2012Although industrial parks are often ... which they reside, they can also consume environmental ... affect human health and quality of life. A ... ( http://www.liebertpub.com/ees ), a peer-reviewed journal from ...
... supercomputer has completed the first phase of an ... powerful scientific computing systems in the world. ... this month. The testing suite included leading scientific ... fusion, and combustion. Jaguar, manufactured by Cray ...
Cached Biology News:Postmenopausal women at greater risk of stroke from high trans fat intake 2Can industrial parks be more environmentally friendly? 2ORNL completes first phase of Titan supercomputer transition 2
2,4-Dinitrophenyl hapten is conjugated to BSA (Bovine Serum Albumin) protein through lysine....
4-Hydroxy-3-iodo-5-nitrophenylacetyl hapten is conjugated to BSA protein through lysine by amide bonds....
Amino Acid Analysis is performed using ion-exchange separation of the amino acids from acid hydrolysates, followed by ninhydrin detection. Typical quantities required are 0.1 to 0.5 mg, depending on...
2,4,6-Trinitrophenyl hapten is conjugated to Bovine Serum Albumin protein through lysine by amide bonds....
Biology Products: